2 results
Approved WMOCompleted
Primary Objective: The primary objective is to determine whether the administration of Gelofusine will reduce the kidney uptake of 111In-labeled exendin in humans by enhancing the excretion of 111In-labeled exendin. These highly relevant data can…
Approved WMOCompleted
The primary study objective is to assess the effect of lanreotideAutogel 120mg administered every 28 days compared to placebo, onprogression-free survival in patients with well or moderatelydifferentiated non functioning entero-pancreatic endocrine…